Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Auric Goldfinger's Short List -- Ignore unavailable to you. Want to Upgrade?

To: lindend who wrote (3033)	9/9/1999 2:03:00 PM
From: Sir Auric Goldfinger	Read Replies (1) \| Respond to of 19428

Wait, LOAX nearing lockup (Oct 18) they'll pump it. Check this out: The Bio-Century Conference begins today in New York City. The following companies will be presenting today: 9:30 AM EDT Idec Pharmaceuticals (IDPH) 10:40 AM EDT Anesta Corp (NSTA) 11:10 AM EDT Coulter Pharmaceuticals (CLTR) 1:20 PM EDT Aronex Pharmaceuticals (ARNX) 2:20 PM EDT Liposome Company (LIPO) Idec CEO Says Estimate for Q3 Rituxan Sales Too High (Correct) 9/9/99 12:42 Idec CEO Says Estimate for Q3 Rituxan Sales Too High (Correct) (Changes first paragraph to indicate sales in third quarter only, updates shares.) New York, Sept. 9 (Bloomberg) -- Idec Pharmaceuticals Corp. Chief Executive William Rastetter said estimates that third- quarter sales of the cancer drug Rituxan would reach $80 million were ``high.' Shares of Idec and Genentech Inc., which helps Idec market the drug, tumbled after his comment, made at an investor conference in New York. Idec fell 17 13/16 to 118 7/8. Genentech fell 6 to 169. Shares in San Diego-based Idec have soared more than seven- fold since October, as sales of its Rituxan treatment for non- Hodgkins lymphoma exceeded company and analyst forecasts. Rituxan, which Idec developed with Genentech Inc., was introduced in October 1997. Last year it had sales of $162.6 million, a record for a cancer treatment in its first year on the market. Genentech, the world's No. 2 biotech company, is majority owned by Swiss drugmaker Roche Holding AG."